Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01208909|
Recruitment Status : Unknown
Verified February 2010 by University of Zurich.
Recruitment status was: Recruiting
First Posted : September 24, 2010
Last Update Posted : October 22, 2010
In the treatment of glioblastoma (GBM) neurosurgical resection of the tumor is usually considered a a first step of effective therapy. Radical resection of the tumor is highly beneficial to the patient as measured in progression-free survival and overall survival. At the same time eloquent areas of the brain have to remain intact to preserve quality of life.
Both 5-ALA fluorescence and intraoperative MRI are used for intraoperative marking of tumor tissue and thereby to improve precision of GBM-Resection.
We now study whether the combination of 5-ALA fluorescence and intraoperative MRI increases the number of sites where tumor tissue can be detected.
- Trial with surgical intervention
|Condition or disease||Intervention/treatment|
|Glioblastoma||Procedure: diagnostic 5-ALA and MRI for tumor resection|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Combined Approach to GBM-resection by 5-ALA and Intraoperative MRI|
|Study Start Date :||August 2009|
|Estimated Primary Completion Date :||December 2011|
|Estimated Study Completion Date :||December 2011|
- Procedure: diagnostic 5-ALA and MRI for tumor resection
diagnostic 5-ALA and MRI for tumor resection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01208909
|Contact: René L. Bernays, MD||+41 (0)44 255 11 11|
|Contact: René L Bernays, MD +41 44 25 ext 5111|
|Study Director:||René L Bernays, MD||UniversitaetsSpital Zuerich|